Mattia Sibona

Dr. Mattia Sibona

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MSMattia Sibona
Mattia Sibona
PDPaolo Destefanis
Paolo Destefanis
EVEugenia Vercelli
Eugenia Vercelli
SSSilvia Secco
Silvia Secco
PGPaolo Gontero
Paolo Gontero
LCLuca Cindolo
Luca Cindolo

18 October 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
PDPaolo Destefanis
Paolo Destefanis
MSMattia Sibona
Mattia Sibona
FVFederico Vitiello
Federico Vitiello
EVEugenia Vercelli
Eugenia Vercelli
LMLuca Micai
Luca Micai
PGPaolo Gontero
Paolo Gontero

16 February 2021 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
PDPaolo Destefanis
Paolo Destefanis
MSMattia Sibona
Mattia Sibona
FSFrancesco Soria
Francesco Soria
EVEugenia Vercelli
Eugenia Vercelli
FVFederico Vitiello
Federico Vitiello
PGPaolo Gontero
Paolo Gontero

Verified
Journal Article
Open access
PDF file
MSMattia Sibona
Mattia Sibona
PDPaolo Destefanis
Paolo Destefanis
MAMarco Agnello
Marco Agnello
BLBeatrice Lillaz
Beatrice Lillaz
MGMattia Giuliano
Mattia Giuliano
PGPaolo Gontero
Paolo Gontero
Objectives: Chronic prostatitis syndrome is a bothering and poorly understood condition. Many patients report genitourinary pain and Lower Urinary Tract Symptoms as a main complaint. Many different pharmacological or behavioural therapies are prescribed in daily clinical practice, but efficacy data are still lacking. The aim of our study was to test the efficacy and safety of a transrectal delivered association of Boswellia resin extract and propolis derived polyphenols for the relief of prostatitis - like symptoms. Materials and methods: Patients affected by chronic/recurrent prostatitis - like symptoms were prospectively enrolled in our study from December, 2016 to December, 2018. Patients were screened at baseline through clinical examination and validated questionnaires administration: Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF). Inclusion criteria were: age ≥ 18; prostatitis symptoms persisting for at least 3 of the last 6 months; CPSI pain domain score ≥ 5; previous negative Meares-Stamey test. Treatment consisted on the administration of 1 suppository containing Boswellia resin extract and propolis derived polyphenols, once a day for 20 days. The primary endpoint of the study was the improvement of quality of life after treatment, defined by a reduction of ≥ 2 points, or ≥ 25%, of mean CPSI pain domain score, compared to baseline. Secondary endpoints were the improvement of post-treatment CPSI total score and the analysis of treatment - related adverse events. All patients were re-evaluated 1 month after treatment. Results: 40 patients were enrolled in our study. Median age (Inter - Quartile Range IQR) was 51.5 (41.5-63.2) years. Mean baseline CPSI scores were: 22.15 (total score), 9.67 (pain domain), 5.15 (micturition domain) and 7.35 (quality of life domain), respectively. No significant adverse events were reported. At 1 month follow-up, CPSI scores appeared modified as follows: 16.40 (total score, p = 0.001); 6.92 (pain domain; p = 0.001; 4.02 (micturition domain, p = 0.09); 5.45 (quality of life domain, p = 0.002). Mean CPSI pain domain score reduction was -2.75 points (-28.5%). Mean CPSI total score reduction was -5.75 points (-26%). Conclusions: The association of Boswellia resin extract and propolis derived polyphenols can reduce genitourinary pain and then improve quality of life of men affected by bothersome prostatitis - like symptoms.

1 January 2018 in Tumori Journal
Verified
Journal Article
Open access
OSOmidreza Sedigh
Omidreza Sedigh
MPMirko Preto
Mirko Preto
FSFarzin Soleimanzadeh
Farzin Soleimanzadeh
GMGiancarlo Marra
Giancarlo Marra
MFMarco Falcone
Marco Falcone
PGPaolo Gontero
Paolo Gontero
Purpose: Inguinal lymphadenectomy (iLAD) reduces mortality in patients with cN0 penile cancer but yields high complication rates. Thus, its prophylactic role has been questioned and dynamic sentinel node biopsy (DSNB) was introduced to select men who should undergo the procedure. Our aim was to investigate the accuracy of a contemporary DSNB cohort. Methods: We performed a retrospective analysis of ≥T1 or ≥G2 cN0 penile cancer undergoing perioperative DSNB from June 2009 to June 2015 at a tertiary referral center. We excluded men with <18 months follow-up or with local recurrence after primary curative treatment. Complications were graded according to the Clavien-Dindo classification. Results: Thirty-five men underwent DSNB; 85.71% had ≤T2 penile cancer with ≤G2a histology. Per groin detection rate was 80% (scintigraphy being positive bilaterally in 60% and unilaterally in 20.0%). In no cases did DSNB prolong the postoperative course compared to primary surgery. Nine men (n = 15/109 nodes removed) had positive results, 8 of whom underwent iLAD. Among negative DSNB patients, 2 developed nodal penile cancer recurrence; none of them had node biopsy due to inconclusive scintigraphy. At a median follow-up of 42 months (interquartile range 30-78 months), if considering only men with scintigraphy detected inguinal nodes, per-patient sensitivity and specificity were 50% and 80% whereas positive predictive value and negative predictive value were 25% and 92.3%, respectively. Conclusions: Perioperative DSNB is a safe procedure, yielding promising results when performed at a tertiary referral center. Future prospective large studies are needed to investigate how to optimize detection rate and reduce false-negative rates.

22 August 2022 in Tomography
Verified
Journal Article
Open access
PDF file
CCCarlo Ceruti
Carlo Ceruti
ACAlessandro Cicerale
Alessandro Cicerale
MDMatteo Diano
Matteo Diano
MSMattia Sibona
Mattia Sibona
CGCaterina Guiot
Caterina Guiot
Federico D'AgataFederico D'Agata
Federico D'Agata
Previous studies demonstrated sex-related differences in several areas of the human brain, including patterns of brain activation in males and females when observing their own bodies and faces (versus other bodies/faces or morphed versions of themselves), but a complex paradigm touching multiple aspects of embodied self-identity is still lacking. We enrolled 24 healthy individuals (12 M, 12 F) in 3 different fMRI experiments: the vision of prototypical body silhouettes, the vision of static images of the face of the participants morphed with prototypical male and female faces, the vision of short videos showing the dynamic transformation of the morphing. We found differential sexual activations in areas linked to self-identity and to the ability to attribute mental states: In Experiment 1, the male group activated more the bilateral thalamus when looking at sex congruent body images, while the female group activated more the middle and inferior temporal gyrus. In Experiment 2, the male group activated more the supplementary motor area when looking at their faces; the female group activated more the dorsomedial prefrontal cortex (dmPFC). In Experiment 3, the female group activated more the dmPFC when observing either the feminization or the masculinization of their face. The defeminization produced more activations in females in the left superior parietal lobule and middle occipital gyrus. The performance of all classifiers built using single ROIs exceeded chance level, reaching an area under the ROC curves > 0.85 in some cases (notably, for Experiment 2 using the V1 ROI). The results of the fMRI tasks showed good agreement with previously published studies, even if our sample size was small. Therefore, our functional MRI protocol showed significantly different patterns of activation in males and females, but further research is needed both to investigate the gender-related differences in activation when observing a morphing of their face/body, and to validate our paradigm using a larger sample.